BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
Amylyx priced an upsized underwritten public offering of 14,090,000 shares at $35.50 for gross proceeds of about $500.2 million, up from the $350.0 million proposed a day earlier, with a 30 day underwriters option on 2,113,500 more shares; closing is expected on or about August 21.
The FDA granted accelerated approval to Ultragenyx's GENGLYCOS (pariglasgene brecaparvovec, formerly DTX401), the first treatment for the underlying cause of glycogen storage disease type Ia and the company's first approved gene therapy, with a rare pediatric disease priority review voucher attached.
The FDA approved Regeneron's Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva; in the 63 patient OPTIMA Phase 3, the 10 mg/kg dose cut new bone lesions 90 percent and flare ups 88 percent versus placebo.
Amgen is terminating its Crohn's disease collaboration with TScan effective November 10, per Fierce Biotech; the 2023 deal carried $30 million upfront and up to $500 million in milestones.
Moderna rose 177 percent on Wednesday and gave back 23.5 percent on Thursday, per market data, as analysts cited by Fierce Biotech set hazard ratio bars for the still undisclosed INTerpath-001 numbers.
Novo's Wegovy pill outsold Lilly's Foundayo roughly five to one in Q2, DKK 3.14 billion versus $98 million, per the companies' quarterly reports.
⚡ Executive Takeaway
The tally is in, and the week's verdict is precise: what a binary costs is set less by its biology than by who is holding it when it resolves. Amylyx held its own coin, won, and sold $500.2 million of new stock at $35.50, a price above where the shares sat before the offering was even announced. We told you Wednesday night the discount was the number to watch. The answer was that there was no discount worth the name. The market charged a proven winner almost nothing for half a billion dollars, upsized it 43 percent, and then bid the stock above the offer price the next day.
Now set that against the other end of the table. Merck and Moderna held the week's biggest binary inside two large balance sheets, disclosed no number, and the market did the pricing for them: Moderna up 177 percent, then down 23.5 percent the following session, per market data. Same week, Amgen quietly handed a $500 million milestone book back to a partner trading below its own cash. Seven columns, one rate card, published in public over five days. The full tally is in tonight's Pro brief. 👉 Read Full Analysis
💰 Capital Markets
The discount we told you to watch came in at roughly zero. AMLX
Amylyx priced 14,090,000 shares at $35.50 on Wednesday evening for about $500.2 million gross, upsizing the deal from the $350.0 million proposed a day earlier, with a 30 day option for 2,113,500 additional shares and closing expected on or about August 21. Leerink, Morgan Stanley, Guggenheim, and LifeSci Capital ran the books; proceeds fund avexitide pre commercial work including manufacturing capacity ahead of the year end NDA. The print is the story: $35.50 sits above the $35.11 close that preceded the offering announcement, about 8 percent below Wednesday's close after the stock had already run, and per market data the shares closed Thursday at $39.66, above the offer price. Silence sold at $13.50 two weeks ago under the same playbook. Column three of the ledger is now complete for the week, and the Pro brief reads what a missing discount actually means.
🧬 Rare Disease
The FDA approved two rare disease drugs in one day, on 44 and 63 patients. RARE | REGN
Wednesday's wires carried two approvals dated the same day. GENGLYCOS (pariglasgene brecaparvovec, formerly DTX401) received accelerated approval for glycogen storage disease type Ia in patients eight and older, Ultragenyx's first gene therapy to clear the agency, on a Phase 3 in which 44 evaluable patients showed a significant cut in daily cornstarch dependence (p<0.001). Ultragenyx puts the US population at 1,500 to 2,500 and collected a rare pediatric disease priority review voucher with the approval. The same day, Regeneron's Pasatru (garetosmab), an Activin A blocking antibody, was approved for adults with fibrodysplasia ossificans progressiva: in the 63 patient OPTIMA trial the 10 mg/kg dose cut new heterotopic ossification lesions 90 percent and flare ups 88 percent versus placebo over 56 weeks, in a disease with roughly 900 diagnosed patients worldwide. Note who else got FDA mail this week: warning letters to an Aurobindo sterile plant and a Tianjin API maker. Biology risk yes, factory risk no, both halves in the same news cycle. The Pro brief maps that budget onto the next three action dates.
💉 Oncology
The market priced the numberless vaccine win on Wednesday, then repriced it on Thursday. MRNA | MRK
Per market data, Moderna rose 177 percent on Wednesday, from $62.96 to $174.38, then gave back 23.5 percent on Thursday to close at $133.32; Merck added 12.6 percent and then eased. The INTerpath-001 hazard ratio is still undisclosed, so the sell side filled the vacuum: per Fierce Biotech, Guggenheim sees adjuvant melanoma sales above $2 billion, and William Blair models $5.4 billion in melanoma, $10 billion in lung, and $3.3 billion in renal by 2040, while warning that the share moves reflect more conviction than the disclosed data support. The bars stand where they were set before the readout: a hazard ratio of 0.65 or better is a clear win, above roughly 0.75 disappoints. BioNTech and Arcturus each rose more than 20 percent on read through, per Fierce. Nothing about the science changed between Wednesday and Thursday. The only thing that moved was the market's willingness to pay for a number it has not seen.
⚖️ Deals and Partnerships
Amgen handed back a $500 million milestone book; Lilly bought its third cheap option in two weeks. AMGN | TCRX | LLY
Amgen is terminating its Crohn's disease target discovery collaboration with TScan effective November 10, citing a strategic portfolio review, per Fierce Biotech. The May 2023 deal paid $30 million upfront with up to $500 million in milestones; TScan says its role was discovery only, nothing changes in its wholly owned programs, and it holds $100.2 million in cash into the second quarter of 2027. It is the second binary returned to sender in recent weeks, after J&J handed prizlon-cel back to AbelZeta, and per market data TScan trades at $0.78, below its own cash. The same day, Lilly signed Amplitude Therapeutics for exclusive rights to trans amplifying RNA vaccine candidates in infectious disease, terms undisclosed, its third platform option after OmniAb and the Sangamo purchase. One balance sheet returning a mature binary while another buys early ones cheaply, in the same news cycle, is column seven and column six of the ledger trading with each other.
💊 Obesity
Round one of the oral obesity duel went to Novo, roughly five to one. NVO | LLY
The first full quarter of head to head oral GLP-1 competition is on the books: Wegovy pill sales of DKK 3.14 billion, about $490 million, versus $98 million for Foundayo in its first quarter, per Novo's half year report and Lilly's Q2 release. BioSpace's analysis of the matchup carries the forward view: GlobalData's Sara Reci notes the efficacy lever has flipped, with oral semaglutide at 16.6 percent weight loss versus Foundayo's 11.2 percent, but still projects Lilly catching up by 2028 and pulling ahead through 2032 behind retatrutide, while Truist's Srikripa Devarakonda argues Lilly's small molecule cost structure wins the price sensitive international markets. Our standing call is unchanged: Novo won the opening quarter on brand and efficacy; the multi year race still tilts to Lilly on cost, capacity, and what comes next. Watch the weekly script data for whether the pill expands the class or cannibalizes the injectable.
📋 Quick Hits
The FDA issued warning letters to Eugia Pharma Specialties, an Aurobindo sterile injectables unit in Hyderabad, and to China's Tianjin Kilo Pharmaceutical, per Fierce Pharma; Eugia was cited for aseptic practice failures with two sister plants already under official action, and Tianjin Kilo for shipping APIs it described as still in development. The factory squeeze continues.
Biokin's izalontamab brengitecan met its PFS primary endpoint in the Chinese Phase 3 Panku-Lung01 trial in EGFR mutant lung cancer after TKI failure, per Fierce Pharma, the fourth China win for the bispecific ADC BMS licensed for $800 million upfront; the global readout comes in 2028. BMY
Vitestro won FDA clearance for an autonomous robotic blood draw device and the FDA opened a public comment period on generative AI regulation, per MedTech Dive.
SK Pharmteco opened two API plants in Ireland, per Fierce Pharma, a data point for the CDMO recovery thesis, and SK Biopharmaceuticals settled its Xcopri generic patent case with MSN, terms not detailed.
Capricor issued no new release and the FDA published no new goal date for deramiocel; the August 22 action date, tomorrow, a Saturday, formally stands, so any written notice would likely land today. CAPR
Still no Senate hearing date for FDA commissioner nominee Heidi Overton; every fourth quarter decision remains with the acting structure.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full seven column binary ledger table: every entry from the week, with dollar values and dates
The Amylyx term sheet and the three day price path from data to pricing to close
Complete GENGLYCOS and Pasatru data tables, endpoints, safety, and patient populations
The analyst bar table on intismeran autogene and the oral obesity Q2 scorecard
📋 The Week in Review
Monday: the through line was set: the binary ledger. Capricor's deferral opened column one and the revived Celgene CVR opened column two.
Tuesday: EyePoint's LUGANO miss and post hoc rescue attempt; AstraZeneca's portfolio day, one loss and two wins absorbed in silence; Slate and Fulcrum filled column five.
Wednesday: the Overton nomination went formal; Amylyx's avexitide cut hypoglycemic events 55 percent; BioMarin and LEO priced the certainty curve in column six.
Thursday: Merck and Moderna won the week's biggest binary and told no one the number; Amylyx went to the wire with a $350 million proposal; Tolerance Bio bought at zero cash; the D.C. Circuit handed Teva a live remand.
Friday: the Amylyx deal priced upsized at $500.2 million with no discount worth the name; GENGLYCOS and Pasatru were approved on 44 and 63 patients; Amgen returned its TScan binary to sender.
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The full seven column tally: every entry and every dollar from the week, the one column that ran exactly on schedule twice, and the single sentence the whole ledger reduces to
💊 The missing discount: what the $35.50 print says the market now charges a proven winner for half a billion dollars, and the anomaly we are hunting for next
📊 Two approvals and two warning letters in one week: the agency's actual risk budget, and how it prices the September 19, September 30, and intismeran files
🎯 Plus the full catalyst calendar, with the Capricor weekend restated and the Amylyx close and TScan termination added
Five days, seven columns, one rate card: the market prices the holder, not the coin. The ledger goes back on the shelf as a standing tool, and Monday we open a new through line. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →